USPTO serial 79444786
KEENOVA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 6, 2026
- Examiner
- WILLIS, ALLYSON B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KEENOVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Mallinckrodt Pharmaceuticals Ireland Limited
IE
Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
Mallinckrodt Pharmaceuticals Ireland Limited
IE
Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
Mallinckrodt Pharmaceuticals Ireland Limited
IE
Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Camille M. Miller
Camille M. Miller Cozen O'Connor1650 Market Street, Suite 2800Philadelphia, PA 19103United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for the treatment of pain management, infectious diseases, central nervous system disorders, namely, epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders; pharmaceutical preparations for the treatment of pain management, infectious diseases, central nervous system disorders, namely, epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer · treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders; ready-to-administer injectable pharmaceutical preparations for the treatment of allergic reactions, hypotension, shock, malignant diseases, and kidney disorders, and to provide and reverse muscle relaxation to be used in patient care facilities, namely, hospitals, acute care facilities, and long term care facilities; radio frequency identification tagged pharmaceutical products for the treatment of cardiovascular, central nervous system, infectious, metabolic, respiratory, gastrointestinal, inflammatory, oncologic, and pain related conditions, namely, sympathomimetic agents, diagnostic agents, anticoagulants, thrombin inhibitors, anesthetics, analgesics, endocrine metabolics, antibacterial agents, antibiotics, skeletal muscle relaxants, injectable estrogens, diuretic agents, psychiatries, antivirals, thyroid agents, corticosteroids, antifungals, immunosuppressive agents, parasympathomimetic agents, vasoconstrictors, oxytocic agents, antiemetics, vasopressin antagonists, vasodilators, vasopressors, anti-epileptics, anticonvulsants, cholinesterase inhibitors, and antimuscarinic agents; pharmaceutical preparations for the treatment of cardiovascular, central nervous system, infectious, metabolic, respiratory, gastrointestinal, inflammatory, oncologic, and pain related conditions; pharmaceutical and medical preparations in connection with critical care, critical testing, maternal health, anesthesia, diseases, kidney disorders, cellulite, skin care, dermatological use, folds, scars, and body contouring and for rejuvenating to-administer injectable pharmaceutical preparations for the treatment of allergic reactions, hypotension, shock, malignant diseases, and kidney disorders, and to provide and reverse muscle relaxation to be used in patient care facilities, namely, hospitals, acute care facilities, and long term care facilities and in doctor's offices; pharmaceutical preparations, namely, analgesics and pain management preparations, preparations for the treatment of cancers, preparations for the treatment of urological diseases and disorders, preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, hormone replacement therapy preparations; drug substances, namely, enzymes for medical purposes; pharmaceutical preparations for the treatment of cellulite; pharmaceutical preparations for skin care; medicated skin care gels and mineral supplements; food supplements; radio frequency identification tagged pharmaceutical products, namely, sympathomimetic agents, diagnostic agents, anticoagulants, thrombin inhibitors, anesthetics, analgesics, endocrine metabolics, antibacterial agents, antibiotics, skeletal muscle relaxants, injectable estrogens, antifungals, immunosuppressive agents, parasympathomimetic agents, vasoconstrictors, oxytocic agents, antiemetics, vasopressin antagonists, vasodilators, vasopressors, anti-epileptics, anticonvulsants, cholinesterase inhibitors, and antimuscarinic agents for the treatment of urinary urgency, breathing, saliva and secretion, gut motility, and heart rate, endocrinology, orthopedics, and urology; pharmaceuticals preparations, namely, a blood clotting aid and delivery system for human use; prefilled syringe containing injectable pharmaceuticals for manual injection for the treatment of pain management, infectious diseases, central nervous system disorders, namely, epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders | ACTIVE | — |
| 035 | Healthcare management services, namely, providing administrative support services to physicians and healthcare providers who prescribe pharmaceutical preparations; outsourcing services in the nature of arranging service contracts or others in the field of pharmaceuticals; business administration of patient reimbursement programs for pharmaceuticals; business administration of patient assistance programs that provide pharmaceuticals to help patients with insufficient resources get treatment at little or no cost to the patient | ACTIVE | — |
| 036 | Providing health insurance information about health insurance benefits to patients; financial administration of patient reimbursement programs for pharmaceuticals; financial administration of patient assistance programs that provide pharmaceuticals to help patients with insufficient resources get treatment at little or no cost to the patient; financial assistance programs that provide pharmaceuticals to help patients with insufficient resources to get treatment at little or no cost to the patient. | ACTIVE | — |
| 040 | Manufacture of pharmaceutical products to the order and specification of others; providing technical information in the field of pharmaceutical manufacturing | ACTIVE | — |
| 042 | Development of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services; medical research in the fields of chemicals and pharmaceuticals; scientific research and testing services in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; development of pharmaceutical products to specifications of others; research and development of pharmaceutical products for others. | ACTIVE | — |
| 044 | Providing medical information and medical information via a website on the subjects of pharmaceutical preparations and medicines, medical devices and techniques; providing medical information and online medical and healthcare information to healthcare professionals and patients; providing medical information via a website; providing medication counseling information, namely, advice and data on the subjects of pharmaceutical preparations and medicine; providing medical information on the subjects of aesthetic solutions to help patents feel better about their bodies. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
- Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
- Other trademarks owned by Mallinckrodt Pharmaceuticals Ireland Limited
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named KEENOVA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 6, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 6, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 18, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 18, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 12, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 21, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 20, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 20, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 20, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 20, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 14, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 14, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 14, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 29, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 29, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 29, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 25, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 25, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 25, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 18, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 2, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 2, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 21, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 20, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 17, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 13, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 13, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 13, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 13, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 26, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 26, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 26, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |